1. Scrip
  2. >>Archive

BioSpecifics appoints board members

 
• By Lucie Ellis-Taitt

Lynbrook, New York-based BioSpecifics Technologies, a biopharmaceutical company developing first-in-class collagenase-based products, has named two new members to its board of directors: Jennifer Chao and Dr Jyrki Mattila. Ms Chao is an advisory analyst at CoreStrategies Management, a strategic consulting firm she founded in 2008 focused on providing transformational strategy and maximizing corporate valuation. Meanwhile, Dr Mattila is chief business officer of iCeutica. Prior to joining iCeutica in 2013, Dr Mattila was president and CEO of LZ Therapeutics.

Lynbrook, New York-based BioSpecifics Technologies, a biopharmaceutical company developing first-in-class collagenase-based products, has named two new members to its board of directors: Jennifer Chao and Dr Jyrki Mattila. Ms Chao is an advisory analyst at CoreStrategies Management, a strategic consulting firm she founded in 2008 focused on providing transformational strategy and maximizing corporate valuation. Meanwhile, Dr Mattila is chief business officer of iCeutica. Prior to joining iCeutica in 2013, Dr Mattila was president and CEO of LZ Therapeutics.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 
• By Andrew McConaghie

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 
• By Andrew McConaghie

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Roivant Staying ‘Patient’ On Deals, Leaving Investors Waiting

 
• By Jessica Merrill

CEO Matt Gline talked to Scrip in an interview about dealmaking and the road back to commercialization.

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

 
• By Kevin Grogan

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial

 
• By Kevin Grogan

A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.